Biohaven Pharmaceutical Holding Company has received orphan drug designation from the FDA for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase inhibitor, for the treatment of multiple system atrophy (MSA).

Irfan Qureshi, M.D., Biohaven Executive Director and development lead for verdiperstat, commented, “We believe verdiperstat has the potential to be the first effective treatment for people living with MSA and we remain on track to start our global Phase 3 clinical trial later this year.”

more